A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Recruiting

Phase 1

Phase 2

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT03972657

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clear Cell Renal Cell Carcinoma (ccRCC)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN5678

Cemiplimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-09. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-04-17.